Extent of lymph node retrieval and pancreatic cancer survival: Information from a large US population database

Annals of Surgical Oncology

Volumn 13, Issue 9, 2006, Pages 1189-1200

  Schwarz, Roderich E ^a   Smith, David D ^b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Lymph node counts; Lymphadenectomy; Pancreatic cancer; Postoperative survival; SEER population data

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; DATA BASE; DUODENUM; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS; PANCREAS CANCER; PROGNOSIS; SEX RATIO; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 33748961333     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9016-x     Document Type: Article

References (36)

1. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997; 21:195-200.
2. Pisters PW, Wolff RA, Crane CH, Evans DB. Combined-modality treatment for operable pancreatic adenocarcinoma. Oncology (Williston Park) 2005; 19:393-404; 409; discussion 409-10, 412-6.
3. Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92:1372-81.
4. Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg 1996; 224:342-7; discussion 347-9.
5. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004; 8:935-49; discussion 949-50.
6. Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996; 223:147-53.
7. Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg 2002; 195:855-64.
8. Havenga K, Enker WE, Norstein J, et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol 1999; 25:368-74.
9. Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998; 228:508-17.
10. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002; 236:355-66; discussion 366-8.
11. Nguyen TC, Sohn TA, Cameron JL, et al. Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg 2003; 7:1-9; discussion 11.
12. Pawlik TM, Abdalla EK, Barnett CC, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg 2005; 140:584-9; discussion 589-91.
13. Surveillance, Epidemiology, and End Results (SEER) Program: public use data (1973-2002). 2005. Available at: http://www.seer.cancer.gov/publicdata/ access.html. Accessed April 8, 2005.
14. Greene FL, Page DL, Fleming ID, et al. (2002) American Joint Committee on Cancer Staging Manual6 Springer Verlag, New York, Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer Staging Manual. 6th ed. New York: Springer Verlag, 2002.
15. Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node counts on staging and survival after gastrectomy for gastric cancer: data from a large U.S. population database. J Clin Oncol 2005; 23:7114-24.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53:457-81.
17. 2/E in the log rank test for survival data or tumor incidence data. Biometrics 1973; 29:579-84.
18. Cox DR. Regression models and life tables. J R Stat Assoc B 1972; 29:187-220.
19. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
20. Henne-Bruns D, Vogel I, Luttges J, Kloppel G, Kremer B. Surgery for ductal adenocarcinoma of the pancreatic head: staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg 2000; 24:595-601; discussion 602.
21. Gazzaniga GM, Cappato S, Papadia F, Mori L, Filauro M. D1 versus D2 pancreatoduodenectomy in surgical therapy of pancreatic head cancer. Hepatogastroenterology 2001; 48:1471-8.
22. Popiela T, Kedra B, Sierzega M. Does extended lymphadenectomy improve survival of pancreatic cancer patients? Acta Chir Belg 2002; 102:78-82.
23. Capussotti L, Massucco P, Ribero D, Vigano L, Muratore A, Calgaro M. Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg 2003; 138:1316-22.
24. Hirata K, Sato T, Mukaiya M, et al. Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg 1997; 132:771-6; discussion 777.
25. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237:74-85.
26. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004; 70:235-40; discussion 240.
27. Gervasoni JE Jr, Taneja C, Chung MA, Cady B. Biologic and clinical significance of lymphadenectomy. Surg Clin North Am 2000; 80:1631-73.
28. Benassai G, Mastrorilli M, Mosella F, Mosella G. Significance of lymph node metastases in the surgical management of pancreatic head carcinoma. J Exp Clin Cancer Res 1999; 18:23-8.
29. Kayahara M, Nagakawa T, Ueno K, Ohta T, Tsukioka Y, Miyazaki I. Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion. Surgery 1995; 117:616-23.
30. Nakao A, Harada A, Nonami T, et al. Lymph node metastases in carcinoma of the head of the pancreas region. Br J Surg 1995; 82:399-402.
31. Sakai M, Nakao A, Kaneko T, et al. Para-aortic lymph node metastasis in carcinoma of the head of the pancreas. Surgery 2005; 137:606-11.
32. Nagakawa T, Kobayashi H, Ueno K, Ohta T, Kayahara M, Miyazaki I. Clinical study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas. Cancer 1994; 73:1155-62.
33. Kayahara M, Nagakawa T, Futagami F, Kitagawa H, Ohta T, Miyazaki I. Lymphatic flow and neural plexus invasion associated with carcinoma of the body and tail of the pancreas. Cancer 1996; 78:2485-91.
34. Yoshida T, Matsumoto T, Sasaki A, Shibata K, Aramaki M, Kitano S. Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. Am J Surg 2004; 187:736-40.
35. Schwarz RE, Smith DD, Keny H, et al. Impact of intraoperative radiation on postoperative and disease-specific outcome after pancreatoduodenectomy for adenocarcinoma: a propensity score analysis. Am J Clin Oncol 2003; 26:16-21.
36. Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 2004; 240:293-8.